Germany’s influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV.
Tag Archive for: Arexvy
The vaccine, branded Arexvy, was approved by the U.S. Food and Drug Administration in June but the Centers for Disease Control and Prevention (CDC) did not recommend RSV shots for adults under 60 years.
The agency approved a label expansion for GSK’s respiratory syncytial virus vaccine Arexvy, allowing its use in adults aged 50 through 59 years who have a medical condition that increases their risk of severe outcomes.
Pfizer on Tuesday unveiled top-line data from its Phase III MONeT trial, showing that its respiratory syncytial virus vaccine Abrysvo could induce immune protection in adults 18 to 59 years of age.
The company beat market estimates for fourth-quarter results today, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off.
CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.
The British biopharma company reported 10% sales growth in the third quarter, driven mainly by robust sales of its respiratory syncytial virus shot Arexvy and shingles vaccine Shingrix.
The British drugmaker’s shot, called Arexvy, met the primary goal in the Phase-III trial of eliciting an immune response in adults of the reported age group who are at an increased risk of catching the virus due to certain underlying medical conditions, the company said.
Last year GSK made a strategic move to focus solely on biopharma, and it is already realizing the benefits of a more targeted business.
British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.